GlucoTrack Drops 24% Despite Successful First-in-Human Study Of CGM

(RTTNews) - GlucoTrack, Inc. (GCTK) is down by 24.56 percent during Tuesday trading despite announcing the successful completion of a first-in-human study for its continuous glucose monitor or CGM.

GCTK is currently trading at $0.86, down $0.17 from the previous close of $1.1400. The stock has fluctuated today, reaching a high of $2.1300 and a low of $0.8900. Trading volume has surged to 43.61 million shares, far exceeding the average volume of 2.35 million. The stock's 52-week range spans from $0.8900 to $99.0000.

The company's device, which directly measures glucose levels from a blood vessel, is implanted in the subclavian vein under the collarbone and does not require an external on-body component.

Although effective, GlucoTrack notes that traditional subcutaneous CGMs still have certain limitations.